참고문헌
- Amelio, I., Cutruzzola, F., Antonov, A., Agostini, M., and Melino, G. (2014). Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39, 191-198. https://doi.org/10.1016/j.tibs.2014.02.004
- Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.K., Shen, M., Bellinger, G., Sasaki, A.T., Locasale, J.W., Auld, D.S., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283. https://doi.org/10.1126/science.1211485
- Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.K., Boxer, M.B., Hong, B.S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012). Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8, 839-847. https://doi.org/10.1038/nchembio.1060
- Bluemlein, K., Gruning, N.M., Feichtinger, R.G., Lehrach, H., Kofler, B., and Ralser, M. (2011). No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2, 393-400. https://doi.org/10.18632/oncotarget.278
- Boxer, M.B., Jiang, J.K., Vander Heiden, M.G., Shen, M., Skoumbourdis, A.P., Southall, N., Veith, H., Leister, W., Austin, C.P., Park, H.W., et al. (2010). Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 53, 1048-1055. https://doi.org/10.1021/jm901577g
- Chaneton, B., and Gottlieb, E. (2012). Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 37, 309-316. https://doi.org/10.1016/j.tibs.2012.04.003
- Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233. https://doi.org/10.1038/nature06734
- Dang, C.V. (2012). Links between metabolism and cancer. Genes Dev. 26, 877-890. https://doi.org/10.1101/gad.189365.112
- DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20. https://doi.org/10.1016/j.cmet.2007.10.002
- Ding, Y., Wang, S., Zhang, M.M., Guo, Y., Yang, Y., Weng, S.Q., Wu, J. M., Qiu, X., and Ding, M.P. (2010). Fructose-1,6-diphosphate inhibits seizure acquisition in fast hippocampal kindling. Neurosci. Lett. 477, 33-36. https://doi.org/10.1016/j.neulet.2010.04.030
- Dombrauckas, J.D., Santarsiero, B.D., and Mesecar, A.D. (2005). Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44, 9417-9429. https://doi.org/10.1021/bi0474923
- Gao, X., Wang, H., Yang, J.J., Liu, X., and Liu, Z. R. (2012). Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598-609. https://doi.org/10.1016/j.molcel.2012.01.001
- Gruning, N.M., Rinnerthaler, M., Bluemlein, K., Mulleder, M., Wamelink, M.M., Lehrach, H., Jakobs, C., Breitenbach, M. and Ralser, M. (2011). Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 14, 415-427. https://doi.org/10.1016/j.cmet.2011.06.017
- Higgins, M.J., and Baselga, J. (2011). Targeted therapies for breast cancer. J. Clin. Invest. 121, 3797-3803. https://doi.org/10.1172/JCI57152
- Imai, K., and Takaoka, A. (2006) Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714-727. https://doi.org/10.1038/nrc1913
- King, A., and Gottlieb, E. (2009). Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr. Opin. Cell Biol. 21, 885-893. https://doi.org/10.1016/j.ceb.2009.09.009
- Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482. https://doi.org/10.1016/j.ccr.2008.05.005
- Kung, C., Hixon, J., Choe, S., Marks, K., Gross, S., Murphy, E., DeLaBarre, B., Cianchetta, G., Sethumadhavan, S., Wang, X., et al. (2012). Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19, 1187-1198. https://doi.org/10.1016/j.chembiol.2012.07.021
- Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R.N., Pandey, A., and Semenza, G.L. (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732-744. https://doi.org/10.1016/j.cell.2011.03.054
- Luo, W., and Semenza, G.L. (2011). Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2, 551-556. https://doi.org/10.18632/oncotarget.299
- Lv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y., et al. (2011). Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730. https://doi.org/10.1016/j.molcel.2011.04.025
- Parnell, K.M., Foulks, J.M., Nix, R.N., Clifford, A., Bullough, J., Luo, B., Senina, A., Vollmer, D., Liu, J., McCarthy, V., et al. (2013). Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 12, 1453-1460. https://doi.org/10.1158/1535-7163.MCT-13-0026
- Sliwoski, G., Kothiwale, S., Meiler, J., and Lowe, E.W., Jr. (2014). Computational methods in drug discovery. Pharmacol. Rev. 66, 334-395.
- Tennant, D.A., Duran, R.V., Boulahbel, H., and Gottlieb, E. (2009). Metabolic transformation in cancer. Carcinogenesis 30, 1269-1280. https://doi.org/10.1093/carcin/bgp070
- Tennant, D.A., Duran, R.V., and Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277. https://doi.org/10.1038/nrc2817
- Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033. https://doi.org/10.1126/science.1160809
- Walsh, M.J., Brimacombe, K.R., Veith, H., Bougie, J.M., Daniel, T., Leister, W., Cantley, L.C., Israelsen, W.J., Vander Heiden, M.G., Shen, M., et al. (2011). 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 21, 6322-6327. https://doi.org/10.1016/j.bmcl.2011.08.114
- Wang, H.J., Hsieh, Y.J., Cheng, W.C., Lin, C.P., Lin, Y.S., Yang, S.F., Chen, C.C., Izumiya, Y., Yu, J.S., Kung, H.J., et al. (2014). JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc. Natl. Acad. Sci. USA 111, 279-284. https://doi.org/10.1073/pnas.1311249111
- Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K. and Lu, Z. (2012a). PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685-696. https://doi.org/10.1016/j.cell.2012.07.018
- Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L.C., and Lu, Z. (2012b). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell. Biol. 14, 1295-1304. https://doi.org/10.1038/ncb2629
피인용 문헌
- Clinical, cellular, and bioinformatic analyses reveal involvement of WRAP53 overexpression in carcinogenesis of lung adenocarcinoma vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317694309
- Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator vol.25, pp.13, 2017, https://doi.org/10.1016/j.bmc.2017.05.004
- Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells vol.336, pp.1, 2015, https://doi.org/10.1016/j.yexcr.2015.05.017
- PHD3 is a transcriptional coactivator of HIF-1α in nucleus pulposus cells independent of the PKM2-JMJD5 axis vol.31, pp.9, 2017, https://doi.org/10.1096/fj.201601291R
- Computer-aided identification of a novel pyruvate kinase M2 activator compound pp.09607722, 2018, https://doi.org/10.1111/cpr.12509
- Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC) pp.17470277, 2018, https://doi.org/10.1111/cbdd.13354
- Pyruvate kinase activators as a therapy target: a patent review 2011-2017 vol.28, pp.1, 2018, https://doi.org/10.1080/13543776.2018.1391218
- Targeting energy metabolism to eliminate cancer cells vol.10, pp.None, 2018, https://doi.org/10.2147/cmar.s167424
- Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment vol.12, pp.2, 2019, https://doi.org/10.1007/s12307-019-00226-0